Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- Endomyocardial biopsy is reserved for when the noninvasive pathway isn't met, such as an abnormal monoclonal screen, equivocal scan, or suspected mixed disease.
- When indicated, biopsy has high sensitivity for cardiac amyloid and serves as the tissue gold standard.
- Histology relies on Congo red staining with apple-green birefringence under polarized light, followed by amyloid typing.
- Typing by immunohistochemistry or mass spectrometry distinguishes ATTR from AL; a negative fat-pad biopsy doesn't exclude cardiac ATTR.
When Endomyocardial Biopsy Is Needed
Most ATTR-CM is now diagnosed without biopsy, so the practical question is when tissue biopsy is still required. Biopsy comes back into play when the noninvasive pathway isn't satisfied: monoclonal-protein screening is abnormal and a light-chain process can't be excluded, bone scintigraphy is equivocal or negative despite clinical suspicion, findings are discordant, or mixed disease is suspected. In other words, tissue biopsy is the answer to a failed or ambiguous noninvasive workup rather than a routine first step.
What Endomyocardial Biopsy Adds
When it’s performed for the right reasons, endomyocardial biopsy is a high-sensitivity test for cardiac amyloid and functions as the tissue gold standard. Sampling the myocardium directly resolves the ambiguity that prompted it by confirming amyloid in the heart and providing material for definitive typing. Because it’s invasive, it’s used selectively, but in the situations above it can convert an uncertain picture into a secure diagnosis, which is why it remains an important component of the diagnostic pathway even when noninvasive confirmation is available.
Histology: Congo Red and Apple-Green Birefringence
The histologic hallmark of amyloid is Congo red staining that produces apple-green birefringence when viewed under polarized light. This step establishes that amyloid is present in the tissue but doesn't by itself identify which protein is responsible. That distinction matters clinically because the treatment pathways for transthyretin and light-chain amyloidosis differ substantially; amyloid confirmation is therefore only the first step in the histologic evaluation.
Amyloid Typing Distinguishes ATTR from AL
After amyloid is confirmed, typing identifies the specific protein, preferably using a validated method such as mass spectrometry, with immunohistochemistry used in appropriate settings. Accurate typing is essential to separate transthyretin (ATTR) from light-chain (AL) amyloidosis and to detect mixed disease, and this is one of the main reasons biopsy is pursued when the noninvasive pathway can't make that distinction. Typing is best performed and interpreted in centers with the relevant expertise, which is part of why coordination with a specialized amyloidosis center is valuable when tissue diagnosis is required.
Why Fat-Pad and Other Tissue Are Limited for Cardiac Confirmation
Sampling more accessible tissue, such as an abdominal fat-pad aspirate, is sometimes used to look for systemic amyloid, but its sensitivity for cardiac ATTR is limited. A positive non-cardiac sample with appropriate typing can be informative, but a negative fat-pad biopsy doesn't exclude cardiac ATTR because the protein may be present in the myocardium without being detectable at a peripheral site. For that reason, when cardiac tissue confirmation is required, endomyocardial biopsy provides the most direct tissue diagnosis.
Practical Checklist for Moving to Tissue
Before requesting endomyocardial biopsy, confirm:
- Is the noninvasive pathway genuinely not met (abnormal monoclonal screen, equivocal or negative scan, discordant findings)?
- Could a light-chain or mixed process explain the picture?
- Will the biopsy include Congo red staining and definitive amyloid typing?
- Is typing available by immunohistochemistry or mass spectrometry?
- If a peripheral sample was negative, is cardiac tissue still needed to settle the question?
Clinical Decision Point
The decision to proceed with biopsy depends on whether the noninvasive diagnostic pathway has been genuinely exhausted or has yielded ambiguous results. When monoclonal screening is abnormal, the scan is equivocal, findings are discordant, or mixed disease is suspected, tissue resolves the question—but only if it includes both confirmation of amyloid and definitive typing to separate ATTR from AL. A negative peripheral sample doesn't close the case; when cardiac confirmation is needed, endomyocardial biopsy is the definitive step, ideally coordinated with an experienced amyloidosis center.
Frequently Asked Questions
When is endomyocardial biopsy needed in ATTR-CM?
Biopsy is needed when the noninvasive pathway isn't met—for example, an abnormal monoclonal-protein screen that can't exclude light-chain disease, an equivocal or negative bone scan despite suspicion, discordant findings, or suspected mixed disease. Biopsy answers an ambiguous workup rather than serving as a routine first step.
What does histology show in cardiac amyloidosis?
Amyloid stains with Congo red and shows apple-green birefringence under polarized light. This confirms amyloid is present but doesn't identify the protein, so typing is needed to determine whether it is ATTR, AL, or mixed disease.
How is amyloid typed?
Typing is most often done with immunohistochemistry or mass spectrometry to identify the specific protein. Accurate typing is essential to distinguish transthyretin from light-chain amyloidosis and to detect mixed disease, and it’s best performed in centers with relevant expertise.
Does a negative fat-pad biopsy rule out ATTR-CM?
No. Fat-pad and other non-cardiac tissue have limited sensitivity for cardiac ATTR, so a negative peripheral sample doesn't exclude the disease. When direct cardiac tissue confirmation is required, endomyocardial biopsy provides the most direct tissue diagnosis.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Confirm the Diagnosis
- Diagnostic Criteria in ATTR-CM
- 99mTc-PYP Scintigraphy and Workup
- Excluding AL and Reading the Phenotype
- Screening and Early Detection in ATTR-CM
Next Clinical Decision
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. Journal of the American College of Cardiology
- Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis. The American Journal of Cardiology
- Amyloid Transthyretin Cardiac Amyloidosis with Different Manifestations, Test Findings and Types. BMJ Case Reports
This content is intended for healthcare professionals for educational purposes and isn't a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.